Target intelligence / Profile preview

Fascin actin-bundling protein 1 (FSCN1)

Target
FSCN1
Molecular classification
Other (Actin-binding protein), Cytoskeletal protein
01

Overview

Fascin actin-bundling protein 1 (FSCN1) is a 55 kDa cytoskeletal protein highly conserved in vertebrates, primarily involved in cross-linking F-actin into tight, parallel bundles. Structurally, fascin contains four β-trefoil domains and at least two major actin-binding sites, which enable its actin-bundling function; dimerization is necessary for activity[1][2][3][4]. It organizes actin filaments to form cell structures such as filopodia, microspikes, and invadopodia, essential for cell migration, membrane dynamics, and invasive behavior[1][5]. Overexpression or dysregulation of fascin is strongly implicated in various human cancers, correlating with enhanced tumor cell migration, invasion, metastasis, and poor clinical outcomes[6]. Because of its central role in cancer cell motility and metastasis, fascin is being pursued as a therapeutic target, with several small-molecule inhibitors in development[3][6]. Fascin is also expressed in normal physiological contexts, including neuronal and immune cells, where it regulates cell structure and movement.

Other names
Fascinp55actin-bundling protein fascinfascin-1
02

Mechanism of action

Inhibitors bind to actin-binding sites, blocking fascin actin-bundling activity, impeding cancer cell migration and invasion[2][3].

03

Biological functions

Actin bundlingCytoskeletal reorganizationCell migrationCell motilityFormation of filopodia, microspikes, invadopodia, and membrane protrusions
04

Disease associations

CancerCancer metastasisTumor progressionPoor prognosis in cancerPotentially neurodevelopmental disorders (suggested by its role in neuronal cell development)
05

Safety considerations

Potential impact on physiological cell motility, neuronal development, and immune cell function due to widespread fascin expressionOff-target effects in normal cells (such as dendritic cells and neurons) expressing fascin
06

Interacting drugs

Macroketone (fascin inhibitor)

1 more in the full profile.

07

Biomarkers

Elevated FSCN1 levels serve as a biomarker for aggressive cancers and poor prognosis[6].

Beyond the preview

Go deeper on Fascin actin-bundling protein 1 (FSCN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fascin actin-bundling protein 1 (FSCN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call